Metronidazolo S.A.L.F.

Metronidazole, the active ingredient in Metronidazolo S.A.L.F., is a nitroimidazole presented as an injectable solution for intravenous use. It treats anaerobic bacterial infections and related conditions in adult patients. GNH USA supplies Metronidazolo S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metronidazole is indicated for a range of anaerobic and protozoal infections. - Anaerobic bacterial infections: effective against mixed anaerobic infections, reducing bacterial load. - Bacterial vaginosis: restores normal vaginal flora by eliminating pathogenic anaerobes. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms and preventing recurrence. - Intra‑abdominal infections: controls polymicrobial infections following surgery or perforation. - Pelvic inflammatory disease: targets anaerobic organisms contributing to pelvic inflammation. - Bacterial sepsis: used as part of combination therapy for severe systemic infections caused by susceptible anaerobes.

Metronidazole may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient alteration of taste perception. - Headache: occasional mild to moderate headache. - Diarrhea: loose stools, usually self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Seizures: rare neurologic events, especially with high doses. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: anaphylaxis, rash, or swelling. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Neutropenia: marked reduction in white blood cells.

Metronidazole requires careful clinical monitoring in several situations. - Renal impairment: adjust dosing and monitor renal function. - Hepatic dysfunction: use with caution and observe liver enzymes. - Alcohol consumption: avoid due to disulfiram‑like reaction. - Pregnancy: safety not established; weigh maternal benefits against potential fetal risk. - Concurrent warfarin therapy: monitor INR closely for increased anticoagulant effect. - Store at room temperature: keep in original container, protect from light and moisture.

Metronidazole interacts with several medicines; some require avoidance, others close monitoring.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: may potentiate anticoagulant effect, increasing INR. - Lithium: may raise lithium concentrations, risking toxicity. - Cimetidine: may increase metronidazole plasma levels. - Phenobarbital: may reduce metronidazole efficacy.

Moderate Interactions (Monitor Closely): - Erythromycin: may increase risk of neurotoxicity. - Ciprofloxacin: may raise seizure risk. - Phenytoin: may lower metronidazole plasma concentrations.